Clinical and biochemical studies support smokeless tobacco's carcinogenic potential in thehumanoral cavity

Cancer Prevention Research

Volumn 7, Issue 1, 2014, Pages 23-32

  Mallery, Susan R ^a,b   Tong, Meng ^a   Michaels, Gregory C ^a   Kiyani, Amber R ^a   Hecht, Stephen S ^c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; NITROSAMINE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE DEHYDROGENASE;

ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DETOXIFICATION; DNA REPLICATION; ESOPHAGUS MUCOSA; EXPOSURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; METABOLIC ACTIVATION; METABOLISM; MOUTH SQUAMOUS CELL CARCINOMA; OUTCOME ASSESSMENT; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKELESS TOBACCO;

BONE AND BONES; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; MOUTH; MOUTH MUCOSA; MOUTH NEOPLASMS; NITROSAMINES; OXYGEN; TOBACCO, SMOKELESS;

EID: 84892429324     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0262     Document Type: Article

References (30)

1. International Agency for Research on Cancer. Smokeless tobacco and tobacco-specific nitrosamines. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: IARC; 2007. v. 89 p. 41-583.
2. Colilla SA. An epidemiologic review of smokeless tobacco health effects and harm reduction potential. Regul Toxicol Pharmacol 2010; 56: 197-211.
3. Lee PN. Summary of the epidemiological evidence relating snus to health. Regul Toxicol Pharmacol 2011;59: 197-214.
4. Boffetta P, Hecht SS, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008;9: 667-75.
5. Hecht SS, Stepanov I, Hatsukami DK. Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. Tob Control 2011;20:443.
6. Kamataki T, Fujita K, Nakayama K, Yamazaki Y, Miyamoto M, Ariyoshi N. Role of human cytochrome P450 (P450) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human P450. Drug Metab Rev 2002;34: 667-76.
7. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992;13: 1789-94.
8. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-Glucuronidation of the lung carcinogen4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 2000;28: 1352-60.
9. Wiener D, Doerge DR, Fang JL, Upadhyaya P, Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 2004;32: 72-9.
10. Rinaldi AL, Morse MA, Fields HW, Rothas DA, Pei P, Rodrigo KA, et al. Curcumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo(a)pyrene-7R-trans-7,8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res 2002;62: 5451-6.
11. Mallery SR, Budendorf DE, Larsen MP, Pei P, Tong M, Holpuch AS, et al. Effects of human oral mucosal tissue, saliva, and oral microflora on intraoral metabolism and bioactivation of black raspberry anthocyanins. Cancer Prev Res 2011;4: 1209-21.
12. Wang S-L, He X-Y, Shen J, Wang J-S, Hong J-Y. The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant. Toxicol Sci 2006;94: 38-45.
13. Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 2009;10: 754-80.
14. Detre S, Saccani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8
15. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012;7:42.
16. Guengerich FP. Metabolism of chemical carcinogens. Carcinogenesis 2000;21: 345-51.
17. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006;6: 947-60.
18. Smith TJ, Liao A, Wang Li-D, Yang G-yu, Starcic S, Philbert AM, et al. Characterization of xenobiotic-metabolizing enzymes and nitrosamine metabolism in the human esophagus. Carcinogenesis 1998;19: 667-72.
19. Hughes SJ, Morse MA, Weghorst CM, Kim H, Watkins PB, Guengerich FP, et al. Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia. Neoplasia 1999;1: 145-53.
20. Wong HL, Murphy SE, Hecht SS. Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N0-nitrosonornicotine enantiomers, N-nitrosopiperidine and N-nitrosopyrrolidine. Chem Res Toxicol 2005;18: 61-9.
21. Jalas JR, Hecht SS, Murphy SE. Cytochrome P450 enzymes as catalysts of metabolism of 4-(Methylnitrosamino)-1(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 2005;18: 95-110.
22. Hecht SS, Carmella SG, Edmonds A, Murphy SE, Stepanov I, Luo X, et al. Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco. Tob Control 2007;17: 128-31.
23. Hecht SS, Carmella SG, Stepanov I, Jensen J, Anderson A, Hatsukami DK. Metabolism of the tobacco-specific carcinogen 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone to its biomarker total NNAL in smokeless tobacco users. Cancer Epidemiol Biomarkers Prev 2008;17: 732-5.
24. Hecht SS, Carmella SG, Murphy SE, Riley WT, Le C, Luo X, et al. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Biomarkers Prev 2007;16: 1567-72.
25. Stepanov I, Yershova K, Carmella S, Upadhyaya P, Hecht SS. Levels of (S)-N0-nitrosonornicotine in U.S. tobacco products. Nicotine Tob Res 2013;15: 1305-10.
26. Lao Y, Yu N, Kassie F, Villalta PW, Hecht SS. Analysis of pyridyloxobutyl DNA adducts in F344 rats chronically treated with (R)- and (S)-N0- nitrosonornicotine. Chem Res Toxicol 2007;20: 246-56.
27. Zhang S, Wang M, Villalta PW, Lindgren BR, Lao Y, Hecht SS. Quantitation of pyridyloxobutyl DNA adducts in nasal and oral mucosa of rats treated chronically with enantiomers of N0-nitrosonornicotine. Chem Res Toxicol 2009;22: 949-56.
28. Balbo S, James-Yi S, Johnson CS, O'Sullivan MG,Stepanov I, Want M, et al. (S)-N0-Nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats. Carcinogenesis 2013;34: 2178-83.
29. Guttenplan JB, Kosinska W, Zhao A-L, Chen K-M, Aliaga C, DelTondo J, et al. Mutagenesis and carcinogenesis induced by dibenzo[a, l]pyrene in the mouse oral cavity: a potential new model for oral cancer. Int J Cancer 2012;130: 2783-90.
30. Chen KM, Guttenplan JB, Zhang SM, Aliaga C, Cooper TK, Sun YW, et al. Mechanisms of oral carcinogenesis induced by dibenzo[a, l]pyrene: an environmental pollutant and a tobacco smoke constituent. Int J Cancer 2013;133: 1300-9.